Skip to main content

Generic Lexapro Approved for Adult Depression, Anxiety


March 14, 2012 — The US Food and Drug Administration (FDA) today approved escitalopram tablets for the treatment of adults with depression and general anxiety disorder, making this the first generic version of Lexapro (Forest Pharmaceuticals) to receive FDA approval for treating both disorders.
"These psychiatric conditions can be disabling and prevent a person from doing everyday activities," Janet Woodcock, MD, director of the FDA's Center for Drug Evaluation and Research, said in a release.
"This medication is widely used by people who must manage their condition over time, so it is important to have affordable treatment options," added Dr. Woodcock.
Today's approval will allow Teva Pharmaceutical Industries/IVAX Pharmaceuticals to market the generic tablets in dosages of 5, 10, and 20 mg. In addition, the FDA granted a 180-day period of generic drug exclusivity to Teva.
The most common treatment-related adverse effects reported in past studies that evaluated this medication have included insomnia, decreased libido, ejaculation disorder, excessive sweating, fatigue, nausea, and drowsiness.
As with other antidepressants, escitalopram comes with a boxed warning and patient medication guide calling for careful monitoring during the start of use and reporting that there is an increased risk for suicidal ideation in those younger than 24 years.
However, the warning also notes that this risk has not been found in those older than 24 years and that those older than 64 years have actually seen a decrease in these behaviors.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

FDA Decision Delayed for Truvada in HIV PrEP

June 11, 2012 — The US Food and Drug Administration (FDA) has delayed its decision on allowing the use of tenofovir disoproxil fumarate/emtricitabine ( Truvada , Gilead) as preexposure prophylaxis (PrEP) so that the proposed risk evaluation and mitigation strategy (REMS) can be reviewed. In early May, the FDA's Antiviral Drugs Advisory Committee  strongly backed  approval of the first-ever drug for the prevention of sexually acquired HIV-1 infection. However, concerns by the panel at the time included that people may neglect condom use if they feel they are protected by PrEP. Panelists were also concerned that uninfected people taking PrEP who become infected with HIV may not switch to a 3-drug regimen as recommended. According to the company, the FDA has postponed the target date to September 14 so it can review Gilead's REMS plan to help ensure that patients will not misuse the drug. The committee's recommendation for supplemental approval of tenofovir/emtricit...
Post a Comment
Read more

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more